Cited by 369Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and LipoproteinsDrug-Induced Hepatotoxicity and Protection

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., Perrillo, R. P.·2004·Alimentary Pharmacology & Therapeutics

DOI 10.1111/j.1365-2036.2004.02025.x

Open this paper in CoChat — free account

Abstract

BACKGROUND: Insulin sensitizing agents may be useful in treatment of non-alcoholic fatty liver disease. AIM: A pilot study to evaluate the efficacy and safety of metformin in non-alcoholic fatty liver disease. METHODS: In an open labelled study, patients with histologically confirmed non-alcoholic fatty liver disease were given metformin (20 mg/kg) for 1 year. Insulin resistance (by log homeostasis assessment model analysis for insulin resistance and Quantitative Insulin Sensitivity Check Index) and post-treatment hepatic histology were compared with pre-treatment histology. RESULTS: Fifteen patients completed 1 year of treatment. During the initial 3 months, there was improvement in alanine aminotransferase and aspartate aminotransferase (P-value 0.01 and 0.02, respectively) along with improvement in insulin sensitivity. However, after 3 months, there was no further improvement in insulin sensitivity and there was gradual rise in aspartate aminotransferase and alanine aminotransferase back to pre-treatment levels. Among the 10 patients with post-treatment biopsy, three (33%), showed improvement in steatosis, two (20%) showed improvement in inflammation score and one (10%) showed improvement in fibrosis. CONCLUSION: Metformin treatment was associated with only a transient improvement in liver chemistries. A progressive, sustainable reduction in insulin sensitivity was not noted during treatment.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2036.2004.02025.x

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931
Nonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Nonalcoholic Steatohepatitis
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Metformin
Bailey, C. J., & Turner, R. C. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602293340906 · Cited by 1,726

Show all 37 references

Research works printed but not linked: 1

10.1002/hep.1840380427 · DOI

Sorted by citations

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Hepatology · doi:10.1002/hep.25762 · Cited by 3,859
Self-citation
AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
Tacke, F., Horn, P., Wai-Sun Wong, V., Ratziu, V., Bugianesi, E., Francque, S., Zelber-Sagi, S., Valenti, L., Roden, M., Schick, F., et al. (2024) · Journal of Hepatology · doi:10.1016/j.jhep.2024.04.031 · Cited by 2,210
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.001 · Cited by 1,805
Self-citation
Cellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,658
A position statement on NAFLD/NASH based on the EASL 2009 special conference
Ratziu, V., Bellentani, S., Cortez‐Pinto, H., Day, C., & Marchesini, G. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.04.008 · Cited by 1,083
Drug-induced liver injury
Andrade, R. J., Chalasani, N., Björnsson, E. S., Suzuki, A., Kullak-Ublick, G. A., Watkins, P. B., Devarbhavi, H., Merz, M., Lucena, M. I., Kaplowitz, N., et al. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0105-0 · Cited by 924
Insulin resistance: a metabolic pathway to chronic liver disease
Bugianesi, E., McCullough, A. J., & Marchesini, G. (2005) · Hepatology · doi:10.1002/hep.20920 · Cited by 900
The Role of Insulin Resistance in Nonalcoholic Fatty Liver Disease
Utzschneider, K. M., & Kahn, S. E. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0587 · Cited by 874
A Randomized Controlled Trial of Metformin versus Vitamin E or Prescriptive Diet in Nonalcoholic Fatty Liver Disease
Bugianesi, E., Gentilcore, E., Manini, R., Natale, S., Vanni, E., Villanova, N., David, E., Rizzetto, M., & Marchesini, G. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41583.x · Cited by 690
Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial
Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625
The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association
Chalasani, N., Younossi, Z. M., Lavine, J. E., Diehl, A. M., Brunt, E. M., Cusi, K. J., Charlton, M., & Sanyal, A. J. (2012) · The American Journal of Gastroenterology · doi:10.1038/ajg.2012.128 · Cited by 594
Self-citation
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Vuppalanchi, R., & Chalasani, N. (2008) · Hepatology · doi:10.1002/hep.22603 · Cited by 568
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
Argo, C. K., Northup, P. G., Al‐Osaimi, A. M. S., & Caldwell, S. H. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.019 · Cited by 560
Spectrum of Liver Disease in Type 2 Diabetes and Management of Patients With Diabetes and Liver Disease
Tolman, K. G., Fonseca, V. A., Dalpiaz, A. S., & Tan, M. H. (2007) · Diabetes Care · doi:10.2337/dc06-1539 · Cited by 533
EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
(2024) · Obesity Facts · doi:10.1159/000539371 · Cited by 545
Non-alcoholic fatty liver disease, obesity and the metabolic syndrome
Dietrich, P., & Hellerbrand, C. (2014) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2014.07.008 · Cited by 468
Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management
García‐Compeán, D., Jáquez-Quintana, J. O., González, J. A., & Maldonado-Garza, H. J. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.280 · Cited by 422
Nonalcoholic fatty liver disease and the metabolic syndrome
Marchesini, G., Marzocchi, R., Agostini, F., & Bugianesi, E. (2005) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000174153.53683.f2 · Cited by 421
Mechanisms of Disease: hepatic steatosis in type 2 diabetes—pathogenesis and clinical relevance
Roden, M. (2006) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0190 · Cited by 407
Non-alcoholic fatty liver disease: The diagnosis and management
El-Kader, S. M. A. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i6.846 · Cited by 398
Alanine aminotransferase as a marker of non‐alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease
Schindhelm, R. K., Diamant, M., Dekker, J. M., Tushuizen, M. E., Teerlink, T., & Heine, R. J. (2006) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.666 · Cited by 376
Diagnosis and Therapy of Nonalcoholic Steatohepatitis
Torres, D. M., & Harrison, S. A. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.077 · Cited by 359
Treatment of non-alcoholic fatty liver disease
Adams, L. A., & Angulo, P. (2006) · Postgraduate Medical Journal · doi:10.1136/pgmj.2005.042200 · Cited by 350
Nonalcoholic Fatty Liver Disease: A Review and Update
Lewis, J. R., & Mohanty, S. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1081-0 · Cited by 350
Abnormal Lipid and Glucose Metabolism in Obesity: Implications for Nonalcoholic Fatty Liver Disease
Parekh, S., & Anania, F. A. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.055 · Cited by 344
Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment, and Outcomes
Ahmed, A., Wong, R. J., & Harrison, S. A. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.07.029 · Cited by 336
Metformin in patients with non-alcoholic fatty liver disease: A randomized, controlled trial
Haukeland, J. W., Konopski, Z., Eggesbø, H. B., von Volkmann, H. L., Raschpichler, G., Bjøro, K., Haaland, T., Løberg, E. M., & Birkeland, K. (2009) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365520902845268 · Cited by 323
Metformin therapy and clinical uses
Scarpello, J. H., & Howlett, H. C. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.027 · Cited by 318
Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma
Hassan, M. M., Curley, S. A., Li, D., Kaseb, A. O., Davila, M. L., Abdalla, E. K., Javle, M. M., Moghazy, D. M., Lozano, R. D., Abbruzzese, J. L., et al. (2010) · Cancer · doi:10.1002/cncr.24982 · Cited by 308
Clinical trial: pilot study of metformin for the treatment of non-alcoholic steatohepatitis
LOOMBA, R., LUTCHMAN, G., KLEINER, D. E., RICKS, M., FELD, J. J., BORG, B. B., MODI, A., NAGABHYRU, P., SUMNER, A. E., LIANG, T. J., et al. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03869.x · Cited by 299
Recommendations for Diagnosis, Referral for Liver Biopsy, and Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Spengler, E. K., & Loomba, R. S. (2015) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2015.06.013 · Cited by 294
The role of adiponectin in the pathogenesis and treatment of non‐alcoholic fatty liver disease
Pοlyzos, S. A., Kountouras, J., Zavos, C., & Tsiaousi, E. (2009) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01176.x · Cited by 282
Pathogenesis and management issues for non-alcoholic fatty liver disease
Duvnjak, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i34.4539 · Cited by 266
A phase 2 clinical trial of metformin as a treatment for non‐diabetic paediatric non‐alcoholic steatohepatitis
Schwimmer, J. B., Middleton, M. S., Deutsch, R., & Lavine, J. E. (2005) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2005.02420.x · Cited by 242
The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis†
Lutchman, G. A., Modi, A. A., Kleiner, D. E., Promrat, K., Heller, T., Ghany, M. G., Borg, B. B., Loomba, R. S., Liang, T. J., Premkumar, A., et al. (2007) · Hepatology · doi:10.1002/hep.21661 · Cited by 240
Drug-induced Liver Injury.
David, S., & Hamilton, J. P. (2010) · PubMed · Cited by 235
Gastrointestinal complications of diabetes mellitus
Krishnan, B. (2013) · World Journal of Diabetes · doi:10.4239/wjd.v4.i3.51 · Cited by 226
Metformin Prevents Alcohol-Induced Liver Injury in the Mouse: Critical Role of Plasminogen Activator Inhibitor-1
Bergheim, I., Guo, L., Davis, M. A., Lambert, J. C., Beier, J. I., Duveau, I., Luyendyk, J. P., Roth, R. A., & Arteel, G. E. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.03.020 · Cited by 204
Liver Disease in Patients With Diabetes Mellitus
Harrison, S. A. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000190774.91875.d2 · Cited by 199
Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients
Noureddin, M., Yates, K. P., Vaughn, I. A., Neuschwander‐Tetri, B. A., Sanyal, A. J., McCullough, A. J., Merriman, R. B., Hameed, B., Doo, E. C., Kleiner, D. E., et al. (2013) · Hepatology · doi:10.1002/hep.26465 · Cited by 202
Non‐alcoholic fatty liver disease from pathogenesis to management: an update
Musso, G., Gambino, R., & Cassader, M. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2009.00657.x · Cited by 200
Efficacy of long-term ezetimibe therapy in patients with nonalcoholic fatty liver disease
Park, H., Shima, T., Yamaguchi, K., Mitsuyoshi, H., Minami, M., Yasui, K., Itoh, Y., Yoshikawa, T., Fukui, M., Hasegawa, G., et al. (2010) · Journal of Gastroenterology · doi:10.1007/s00535-010-0291-8 · Cited by 197
Non-alcoholic steatohepatitis: From cell biology to clinical practice
Cortez‐Pinto, H., de Moura, M. C., & Day, C. P. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.09.002 · Cited by 194
The Role of Metformin in the Management of NAFLD
Mazza, A., Fruci, B., Garinis, G. A., Giuliano, S., Malaguarnera, R., & Belfiore, A. (2011) · Experimental Diabetes Research · doi:10.1155/2012/716404 · Cited by 189
Non-alcoholic Fatty Liver Disease and Metabolic Syndrome—Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology
Duseja, A. K., Singh, S. P., Saraswat, V. A., Acharya, S. K., Chawla, Y. K., Chowdhury, S., Dhiman, R. K., Jayakumar, R. V., Madan, K., Misra, S. P., et al. (2015) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2015.02.006 · Cited by 193
The Asia–Pacific Working Party on Non‐alcoholic Fatty Liver Disease guidelines 2017—Part 2: Management and special groups
Chitturi, S., Wong, V. W., Chan, W., Wong, G. L., Wong, S. K., Sollano, J. D., Ni, Y., Liu, C., Lin, Y., Lesmana, L. A., et al. (2017) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.13856 · Cited by 185
Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective
Gusdon, A. M., Song, K., & Qu, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/637027 · Cited by 172
Nonalcoholic Fatty Liver Disease as a Complication of Insulin Resistance
Abdelmalek, M. F., & Diehl, A. M. (2007) · Medical Clinics of North America · doi:10.1016/j.mcna.2007.06.001 · Cited by 170
Self-citation
Effects of Natural Products on Fructose-Induced Nonalcoholic Fatty Liver Disease (NAFLD)
Chen, Q., Wang, T., Li, J., Wang, S., Qiu, F., Yu, H., Zhang, Y., & Wang, T. (2017) · Nutrients · doi:10.3390/nu9020096 · Cited by 168
Review article: current management of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis
Younossi, Z. M. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03710.x · Cited by 167
Mitochondrial Dysfunction: A Basic Mechanism in Inflammation-Related Non-Communicable Diseases and Therapeutic Opportunities
Hernández‐Aguilera, A., Rull, A., Rodríguez‐Gallego, E., Riera-Borrull, M., Luciano‐Mateo, F., Camps, J., Menéndez, J. A., & Joven, J. (2013) · Mediators of Inflammation · doi:10.1155/2013/135698 · Cited by 167
Nonalcoholic Fatty Liver Disease in Women
Suzuki, A., & Abdelmalek, M. F. (2009) · Women s Health · doi:10.2217/17455057.5.2.191 · Cited by 157
Betaine improved adipose tissue function in mice fed a high-fat diet: a mechanism for hepatoprotective effect of betaine in nonalcoholic fatty liver disease
Wang, Z., Yao, T., Pini, M., Zhou, Z., Fantuzzi, G., & Song, Z. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00249.2009 · Cited by 153
Review article: epidemiology, pathogenesis and potential treatments of paediatric non‐alcoholic fatty liver disease
Barshop, N. J., Sirlin, C. B., Schwimmer, J. B., & Lavine, J. E. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03703.x · Cited by 144
Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD)
Alwahsh, S. M., & Gebhardt, R. (2016) · Archives of Toxicology · doi:10.1007/s00204-016-1892-7 · Cited by 143
Impact of obesity on treatment of chronic hepatitis C†
Charlton, M., Pockros, P. J., & Harrison, S. A. (2006) · Hepatology · doi:10.1002/hep.21239 · Cited by 139
Mechanisms and implications of age-related changes in the liver: nonalcoholic Fatty liver disease in the elderly
Gan, L., Chitturi, S., & Farrell, G. C. (2011) · Current Gerontology and Geriatrics Research · doi:10.1155/2011/831536 · Cited by 135
Clinical approaches to non-alcoholic fatty liver disease
Schwenger, K. J. P. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i7.1712 · Cited by 139
Silymarin in non alcoholic fatty liver disease
Cacciapuoti, F. (2013) · World Journal of Hepatology · doi:10.4254/wjh.v5.i3.109 · Cited by 134
Diabetes and liver disease: An ominous association
Moscatiello, S., Manini, R., & Marchesini, G. (2006) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2006.08.004 · Cited by 131
INTERDISCIPLINARY CLINICAL PRACTICE GUIDELINES "MANAGEMENT OF OBESITY AND ITS COMORBIDITIES"
Dedov, I. I., Shestakova, M. V., Mel'nichenko, G. A., Mazurina, N. V., Andreeva, E. N., Bondarenko, I. Z., Руслановна, Г. З., Dzgoeva, F. K., Елисеев, М. С., Ershova, E. V., et al. (2021) · Obesity and metabolism · doi:10.14341/omet12714 · Cited by 163
Metformin versus dietary treatment in nonalcoholic hepatic steatosis: a randomized study
Garinis, G. A., Fruci, B., Mazza, A., Siena, M. D., Abenavoli, S., Gulletta, E., Ventura, V., Greco, M., Abenavoli, L., & Belfiore, A. (2010) · International Journal of Obesity · doi:10.1038/ijo.2010.40 · Cited by 127
Metformin use in children with nonalcoholic fatty liver disease: An open-label, 24-month, observational pilot study
Nobili, V., Manco, M., Ciampalini, P., Alisi, A., Vito, R. D., Bugianesi, E., MARCELLINI, M., & Marchesini, G. (2008) · Clinical Therapeutics · doi:10.1016/j.clinthera.2008.06.012 · Cited by 125
Mechanisms and clinical implications of hepatocyte lipoapoptosis
Cazanave, S. C., & Gores, G. J. (2010) · Clinical Lipidology · doi:10.2217/clp.09.85 · Cited by 122
Review article: diagnosis and treatment of non‐alcoholic fatty liver disease
OH, M. K., Winn, J., & Poordad, F. F. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2008.03752.x · Cited by 120
The Effect of a Silybin-Vitamin E-Phospholipid Complex on Nonalcoholic Fatty Liver Disease: A Pilot Study
Loguercio, C., Federico, A., Trappoliere, M., Tuccillo, C., de Sio, I., Di Leva, A., Niosi, M., D’Auria, M. V., Capasso, R., Blanco, C. D. V., et al. (2007) · Digestive Diseases and Sciences · doi:10.1007/s10620-006-9703-2 · Cited by 116
Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease
Omer, Z., Çetinkalp, Ş., Akyıldız, M., Yılmaz, F., Batur, Y., Yılmaz, C., & Akarca, U. S. (2009) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e32832e2baf · Cited by 117
Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis
Angelico, F., Burattin, M., Alessandri, C., Ben, M. D., & Lirussi, F. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005166.pub2 · Cited by 118
Retracted
Non-alcoholic fatty liver disease and insulin resistance: From bench to bedside
Gariani, K., Philippé, J., & Jornayvaz, F. R. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.11.002 · Cited by 113
Liver disease and diabetes: Association, pathophysiology, and management
Ahmadieh, H., & Azar, S. T. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.01.003 · Cited by 112
Meta-analysis of randomized controlled trials of pharmacologic agents in non-alcoholic steatohepatitis
Said, A., & Akhter, A. (2017) · Annals of Hepatology · doi:10.5604/01.3001.0010.0284 · Cited by 111
New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD)
Ali, R., & Cusi, K. J. (2009) · Annals of Medicine · doi:10.1080/07853890802552437 · Cited by 111
Nonalcoholic Fatty Liver Disease
Kopec, K. L., & Burns, D. L. (2011) · Nutrition in Clinical Practice · doi:10.1177/0884533611419668 · Cited by 114
Combination of N ‐acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non‐alcoholic steatohepatitis
de Oliveira, C. P. M. S., Stefano, J. T., de Siqueira, É. R. F., Silva, L. S., Mazo, D. F. D. C., de Lima, V. M. R., Junior, C. K. F., de Mello, E. S., Souza, F., Rabelo, F., et al. (2007) · Hepatology Research · doi:10.1111/j.1872-034x.2007.00215.x · Cited by 109
Review: Treatment options for nonalcoholic fatty liver disease
Lam, B. P., & Younossi, Z. M. (2010) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x09359964 · Cited by 108
Nonalcoholic Fatty Liver: A Possible New Target for Type 2 Diabetes Prevention and Treatment
Fruci, B., Giuliano, S., Mazza, A., Malaguarnera, R., & Belfiore, A. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141122933 · Cited by 109
Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents
Nadeau, K. J., Ehlers, L. B., Zeitler, P. S., & Love‐Osborne, K. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2008.00450.x · Cited by 106
Clinical trial: a nutritional supplement Viusid, in combination with diet and exercise, in patients with nonalcoholic fatty liver disease
VILAR GOMEZ, E., RODRIGUEZ DE MIRANDA, A., GRA ORAMAS, B., ARUS SOLER, E., LLANIO NAVARRO, R., CALZADILLA BERTOT, L., YASELLS GARCIA, A., & DEL ROSARIO ABREU VAZQUEZ, M. (2009) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2009.04122.x · Cited by 105
Hepatogenous diabetes. Current views of an ancient problem
García‐Compeán, D., Jáquez-Quintana, J. O., & Maldonado-Garza, H. J. (2009) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31805-8 · Cited by 105
Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine
Brandt, A., Hernández-Arriaga, A. M., Kehm, R., Sánchez, V., Jin, C. J., Nier, A., Baumann, A., Camarinha‐Silva, A., & Bergheim, I. (2019) · Scientific Reports · doi:10.1038/s41598-019-43228-0 · Cited by 108
Non-alcoholic fatty liver disease and cardiovascular risk
Brea, Á., & Puzo, J. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.085 · Cited by 109
Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions
Duseja, A. K., Das, A., Dhiman, R. K., Chawla, Y. K., Thumburu, K. K., Bhadada, S. K., & Bhansali, A. K. (2007) · Annals of Hepatology · doi:10.1016/s1665-2681(19)31902-7 · Cited by 100
Metformin and metabolic diseases: a focus on hepatic aspects
Zheng, J., Woo, S., Hu, X., Botchlett, R. E., Chen, L., Huo, Y., & Wu, C. (2015) · Frontiers of Medicine · doi:10.1007/s11684-015-0384-0 · Cited by 101
Recent advances in nonalcholic fatty liver disease
Greenfield, V., Cheung, O., & Sanyal, A. J. (2008) · Current Opinion in Gastroenterology · doi:10.1097/mog.0b013e3282fbccf2 · Cited by 94
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets
Younossi, Z. M., Reyes, M. J., Mishra, A., Mehta, R., & Henry, L. L. (2013) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12543 · Cited by 93
The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease
Nar, A., & Gedik, O. (2008) · Acta Diabetologica · doi:10.1007/s00592-008-0067-2 · Cited by 90
Silymarin attenuated hepatic steatosis through regulation of lipid metabolism and oxidative stress in a mouse model of nonalcoholic fatty liver disease (NAFLD).
Ni, X., & Wang, H. (2016) · PubMed Central · Cited by 89
Systematic review: Preventive and therapeutic applications of metformin in liver disease
Bhat, A. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i12.1652 · Cited by 87
The metabolic syndrome and nonalcoholic fatty liver disease in children
Sundaram, S. S., Zeitler, P. S., & Nadeau, K. J. (2009) · Current Opinion in Pediatrics · doi:10.1097/mop.0b013e32832cb16f · Cited by 85
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status
Stein, L. L., Dong, M. H., & Loomba, R. S. (2009) · Advances in Therapy · doi:10.1007/s12325-009-0072-z · Cited by 85
Current treatment of non‐alcoholic fatty liver disease
Ahmed, M. H., & Byrne, C. D. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00926.x · Cited by 84
Diabetes Mellitus and Risk of Hepatocellular Carcinoma
Li, X., Wang, X., & Gao, P. (2017) · BioMed Research International · doi:10.1155/2017/5202684 · Cited by 88
Therapy of nonalcoholic fatty liver disease: current status.
Duvnjak, M., Tomašić, V., Gomerčić, M., Duvnjak, L. S., Baršić, N., & Lerotić, I. (2009) · PubMed · Cited by 82
Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study
Athyros, V. G., Γιουλεμέ, Ό., Ganotakis, E. S., Elisaf, M., Τζιόμαλος, Κ., Vassiliadis, T. G., Liberopoulos, E. N., Theocharidou, E., Karagiannis, A. I., & Mikhailidis, D. P. (2011) · Archives of Medical Science · doi:10.5114/aoms.2011.25554 · Cited by 82
Effects of Metformin on Hepatic Steatosis in Adults with Nonalcoholic Fatty Liver Disease and Diabetes: Insights from the Cellular to Patient Levels
Pinyopornpanish, K., Leerapun, A., Pinyopornpanish, K., & Chattipakorn, N. (2021) · Gut and Liver · doi:10.5009/gnl20367 · Cited by 86
Therapeutic Trials in Nonalcoholic Steatohepatitis
Ratziu, V., Caldwell, S. H., & Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.24042 · Cited by 76

Authors: Nair, S., Diehl, A. M., Wiseman, M., Farr, G. H., & Perrillo, R. P.
Affiliations: Ochsner Medical Center (US)
Johns Hopkins University (US)
Corresponding author: Nair, S.
ORCID: Nair, S.
Diehl, A. M.
Venue: Alimentary Pharmacology & Therapeutics
Publisher: Wiley
Published: 2004-06-14
Volume: 20
Issue: 1
Pages: 23-28
ISSN: 0269-2813 (ISSN-L)
1365-2036
DOI: 10.1111/j.1365-2036.2004.02025.x
OpenAlex: W2056505063
Cited by: 369
References: 37
Citations by year: 2026: 1 · 2025: 3 · 2024: 13 · 2023: 13 · 2022: 7 · 2021: 10 · 2020: 9 · 2019: 6 · 2018: 14 · 2017: 13 · 2016: 9 · 2015: 22 · 2014: 21 · 2013: 21 · 2012: 17
FWCI: 20.68
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: Alimentary Pharmacology & Therapeutics (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
Keywords: metformin, nonalcoholic steatohepatitis, non-alcoholic fatty liver disease, insulin sensitizers, insulin resistance, HOMA-IR, QUICKI, hepatic steatosis, liver fibrosis, liver inflammation, alanine aminotransferase, aspartate aminotransferase, drug safety and efficacy
MeSH terms: Alanine Transaminase, Aspartate Aminotransferases, Drug Evaluation, Female, Hepatitis, Humans, Hypoglycemic Agents, Insulin Resistance, Male, Metformin, Middle Aged, Patient Compliance, Pilot Projects, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks